- Lobbying
- Lobbying by Biotechnology Innovation Organization
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Joseph Vasapoli | Min. Counsel, Energy&Comm, Special Asst. DOE |
Jeffery Mortier | Prof Staff on E&C Cmte and LA Rep Whitfield Prof Staff on E&C Cmte, LA Rep Whitfield and Intern Devin Nunes |
Jeffrey MacKinnon | LD & LA Rep. Joe Barton (RTexas) |
Sarah Walter | Former Legislative Director/Chief Counsel, Sen. John Breaux Former Legislative Director/Chief Counsel, Sen. John Breaux |
J. Daniel Walsh | LD Rep. Wayne Gilchrest and LA Rep. Jack Buechner |
Edward Whitfield | U.S. Representative (21 yrs.) |
Kristen O'Neill | Health Policy Advisory, LA, Staff Assistant Gene Greene (D-TX) Staff Assistant GK Butterfield (D-NC) |
Jody Gale | n/a |
William Krieger | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Pharmacy
Registration
Issue(s) they said they’d lobby about: Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program.
Medicare Part B Demonstration. Issues related to the implementation of the follow-on biologics provisions in P.L. 111148 "Patient Protection and Affordable Care Act".
Issues related to the Prescription Drug User Fee Act and American Health Care Act.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate